BioVie Reports Positive Phase 2 Parkinson’s Trial Data
The Phase 2 SUNRISE-PD trial found that bezisterim treatment led to motor and non-motor symptom improvements.
Updated on Oct. 20, 2026 in Alzheimer’s
Live Poll
Do you trust that new clinical drug trial results will lead to better Parkinson's treatments?
BioVie announced results from its Phase 2 SUNRISE-PD clinical trial showing that the drug bezisterim improved Parkinson's disease symptoms. Participants with higher systemic inflammation experienced the strongest clinical responses during the 12-week study.
Why it matters
The study successfully established proof-of-concept for bezisterim, providing the data necessary to design a pivotal registrational Phase 3 trial. These findings represent a significant step in developing new therapeutic options for early-stage Parkinson's disease.
The 12-week trial enrolled 57 participants, with a composite benefit score favoring bezisterim at a Cohen's d of -1.61. Patients with systemic inflammation exceeding 230 x 10^9/L in platelet counts showed the most significant symptom relief.
The players
BioVie
This Carson City, Nevada-based clinical-stage company focuses on developing innovative therapies for chronic neurological and liver diseases.
The details
Administered via a hybrid decentralized model, the trial used video-linked physician supervision to monitor 20 mg twice-daily doses. Patients receiving the treatment demonstrated significant improvements in MDS-UPDRS Part I, Part III, and Total Scores without reporting any severe or serious adverse events.
Timeline
October 17-20, 2026: The American Neurological Association Annual Meeting was held in San Diego.
October 20, 2026: BioVie announced the Phase 2 clinical trial results.
Health Landscape
The SUNRISE-PD trial results extend the current clinical development pipeline for neuroinflammatory Parkinson's therapies by providing new evidence for potential Phase 3 efficacy. This approach signals a shift toward addressing systemic inflammation as a driver of motor and non-motor symptoms in early-stage disease.
Patients with early-stage Parkinson's disease may gain new treatment options if future Phase 3 trials confirm these preliminary results. The study also highlights how decentralized clinical trials can improve access for patients who prefer home-based participation.
The takeaway
This trial underscores the potential for targeting systemic inflammation to manage neurodegenerative symptom progression. Patients and caregivers should continue to consult with movement disorder specialists as the company moves toward registrational trials.
Further reading
For broader context on neurodegenerative research, visit Alzheimer’s.
Live Poll
Do you trust that new clinical drug trial results will lead to better Parkinson's treatments?
